Marcel Hibert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1334636/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. Cardiovascular Research, 2020, 116, 686-697.	3.8	54
2	A Nonpeptide Oxytocin Receptor Agonist for a Durable Relief of Inflammatory Pain. Scientific Reports, 2020, 10, 3017.	3.3	31
3	From the Promiscuous Asenapine to Potent Fluorescent Ligands Acting at a Series of Aminergic G-Protein-Coupled Receptors. Journal of Medicinal Chemistry, 2018, 61, 174-188.	6.4	13
4	Versatile Synthetic Approach for Selective Diversification of Bicyclic Aza-Diketopiperazines. ACS Omega, 2018, 3, 15182-15192.	3.5	4
5	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. Journal of Medicinal Chemistry, 2018, 61, 8670-8692.	6.4	33
6	Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia. Journal of Medicinal Chemistry, 2018, 61, 7671-7686.	6.4	26
7	Comparative Study of the Synthesis and Structural and Physicochemical Properties of Diketopiperazines vs Aza-diketopiperazines. Journal of Organic Chemistry, 2017, 82, 3239-3244.	3.2	7
8	A step-economical multicomponent synthesis of 3D-shaped aza-diketopiperazines and their drug-like chemical space analysis. Organic and Biomolecular Chemistry, 2016, 14, 8859-8863.	2.8	9
9	A strategy to discover decoy chemokine ligands with an anti-inflammatory activity. Scientific Reports, 2015, 5, 14746.	3.3	22
10	Selective Nonpeptidic Fluorescent Ligands for Oxytocin Receptor: Design, Synthesis, and Application to Time-Resolved FRET Binding Assay. Journal of Medicinal Chemistry, 2015, 58, 2547-2552.	6.4	19
11	Time-Resolved FRET Binding Assay to Investigate Hetero-Oligomer Binding Properties: Proof of Concept with Dopamine D ₁ /D ₃ Heterodimer. ACS Chemical Biology, 2015, 10, 466-474.	3.4	39
12	Diastereoselective synthesis of novel aza-diketopiperazines <i>via</i> a domino cyclohydrocarbonylation/addition process. Chemical Communications, 2014, 50, 9657-9660.	4.1	15
13	Structure–Activity Relationship Studies toward the Discovery of Selective Apelin Receptor Agonists. Journal of Medicinal Chemistry, 2014, 57, 2908-2919.	6.4	27
14	An Antedrug of the CXCL12 Neutraligand Blocks Experimental Allergic Asthma without Systemic Effect in Mice. Journal of Biological Chemistry, 2013, 288, 11865-11876.	3.4	32
15	Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo. ACS Medicinal Chemistry Letters, 2012, 3, 10-14.	2.8	26
16	Why and how to find neutraligands targeting chemokines?. Drug Discovery Today: Technologies, 2012, 9, e245-e251.	4.0	3
17	Fluorescent Derivatives of AC-42 To Probe Bitopic Orthosteric/Allosteric Binding Mechanisms on Muscarinic M1 Receptors. Journal of Medicinal Chemistry, 2012, 55, 2125-2143.	6.4	33
18	Selective Fluorescent Nonpeptidic Antagonists For Vasopressin V ₂ GPCR: Application To Ligand Screening and Oligomerization Assays Journal of Medicinal Chemistry, 2012, 55, 8588-8602.	6.4	52

MARCEL HIBERT

#	Article	IF	CITATIONS
19	Combinatorial Aid for Underprivileged Scaffolds: Solution and Solid-phase Strategies for a Rapid and Efficient Access To Novel Aza-diketopiperazines (Aza-DKP). ACS Combinatorial Science, 2012, 14, 323-334.	3.8	26
20	Identification of Nonpeptide Oxytocin Receptor Ligands by Receptorâ€Ligand Fingerprint Similarity Search. Molecular Informatics, 2011, 30, 521-526.	2.5	14
21	Identification and pharmacological properties of E339–3D6, the first nonpeptidic apelin receptor agonist. FASEB Journal, 2010, 24, 1506-1517.	0.5	95
22	Subtlety of the Structureâ dffinity and Structureâ dEfficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist. Journal of Medicinal Chemistry, 2010, 53, 1546-1562.	6.4	19
23	Small Neutralizing Molecules to Inhibit Actions of the Chemokine CXCL12. Journal of Biological Chemistry, 2008, 283, 23189-23199.	3.4	85
24	A novel, conformationâ€specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB Journal, 2007, 21, 2124-2134.	0.5	81
25	Solid-Phase Preparation of a Pilot Library Derived from the 2,3,4,5-Tetrahydro-1H-benzo[b]azepin-5-amine Scaffold. ACS Combinatorial Science, 2007, 9, 487-500.	3.3	33
26	On the Use of Nonfluorescent Dye Labeled Ligands in FRET-Based Receptor Binding Studies. Journal of Medicinal Chemistry, 2005, 48, 7847-7859.	6.4	26
27	Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. Journal of Medicinal Chemistry, 1992, 35, 3448-3462.	6.4	435